Title: METHODS FOR INHIBITING PROTEASESOME

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(85) Abstract: The present invention relates to methods for inhibiting proteasome comprising administering to mammals in need thereof a compound having Formula (I).
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/4184, 31/69, 31/675, 38/05
US CL : 514/19, 64, 393, 424

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/19, 64, 393, 424

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 02/48157 A2 (BRISTOL-MYERS SQUIBB PHARM COMPANY) 20 June 2002 (20.06.2002), see entire document.</td>
<td>10</td>
</tr>
<tr>
<td>X</td>
<td>WO 91/39773 A1 (SMITHKLINE BEECHAM CORPORATION) 07 June 2001 (07.06.2001), see entire document.</td>
<td>10</td>
</tr>
<tr>
<td>X</td>
<td>WO 01/07407 A1 (DU PONT PHARMACEUTICALS COMPANY) 01 February 2001 (01.02.2001), see entire document.</td>
<td>10</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
13 November 2004 (13.11.2004)

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703) 305-3230

Authorized officer
Brian Kwon
Telephone No. (571) 272-1600

Date of mailing of the international search report
17 NOV 2004

Form PCT/ISA/210 (second sheet) (January 2004)
Continuation of B. FIELDS SEARCHED Item 3:
STN ONLINE
search terms: proteasome, cancer, tumour neoplasrn, lactam acylaminokaneboronate